{
    "organizations": [],
    "uuid": "e15df2f12d04a3f0737f453a80c307c0b1f831a1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puretech-says-follica-rain-pivotal/brief-puretech-says-follica-rain-pivotal-study-expected-to-commence-following-completion-of-ongoing-optimisation-study-idUSFWN1QA093",
    "ord_in_thread": 0,
    "title": "BRIEF-Puretech Says ‍Follica Rain Pivotal Study Expected To Commence Following Completion Of Ongoing Optimisation Study​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Puretech Health Plc:\n* ‍FOLLICA RAIN PIVOTAL STUDY IS EXPECTED TO COMMENCE FOLLOWING COMPLETION OF AN ONGOING OPTIMISATION STUDY​\n* ‍OVER NEXT 12 MONTHS, REGULATORY FILINGS ANTICIPATED FROM BOTH AKILI AND GELESIS WITH FDA IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-20T15:33:00.000+02:00",
    "crawled": "2018-02-21T21:38:38.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "puretech",
        "health",
        "plc",
        "rain",
        "pivotal",
        "study",
        "expected",
        "commence",
        "following",
        "completion",
        "ongoing",
        "optimisation",
        "next",
        "month",
        "regulatory",
        "filing",
        "anticipated",
        "akili",
        "gelesis",
        "fda",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}